When Biotechs Get Breakthrough Therapy Status, Mr. Market Yawns

As a biotech consultant, I’ve heard many CEO’s tell me that a “drumbeat of news” is critical to sustain investors’ interest during the never-ending fundraising process – but I’ve never been convinced how much it moves the needle.